For adults with relapsing-remitting multiple sclerosis (RRMS), what are the benefits and risks of natalizumab compared with placebo, and compared with biosimilar natalizumab?

Cochrane Clinical Answers 2026

View at publisher

Authors: Aileen A. Antonio‐Santos

DOI: 10.1002/cca.4698

Cited by: 0

References: 1

Fields of Study & Subjects

Multiple Sclerosis Research Studies Psoriasis: Treatment and Pathogenesis Inflammatory Bowel Disease

References 1